AUTHOR=Shang Rui , Rodrigues Brian 

TITLE=Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease

JOURNAL=Journal of Pharmacy & Pharmaceutical Sciences

VOLUME=Volume 27 - 2024

YEAR=2024

URL=https://www.frontierspartnerships.org/journals/journal-of-pharmacy-pharmaceutical-sciences/articles/10.3389/jpps.2024.13199

DOI=10.3389/jpps.2024.13199

ISSN=1482-1826

ABSTRACT=Worldwide, the prevalence of obesity and diabetes have increased, with heart 18 disease being their leading cause of death. Traditionally, the management of 19 obesity and diabetes has focused mainly on weight reduction and controlling high 20 blood glucose. Unfortunately, despite these efforts, poor medication 21 management predisposes these patients to heart failure. One instigator for the 22 development of heart failure is how cardiac tissue utilizes different sources of fuel 23 for energy. In this regard, the heart switches from using various substrates, to 24 predominantly using fatty acids (FA). This transformation to using FA as an 25 exclusive source of energy is helpful in the initial stages of the disease. However, 26 over the progression of diabetes this has grave end results. This is because toxic 27 by-products are produced by overuse of FA, which weaken heart function (heart 28 disease). Lipoprotein lipase (LPL) is responsible for regulating FA delivery to the 29 heart, and its function during diabetes has not been completely revealed. In this 30 review, the mechanisms by which LPL regulates fuel utilization by the heart in 31 control conditions and following diabetes will be discussed in an attempt to 32 identify new targets for therapeutic intervention. Currently, as treatment options 33 to directly target diabetic heart disease are scarce, research on LPL may assist 34 in drug development that exclusively targets fuel utilization by the heart and lipid 35 accumulation in macrophages to help delay, prevent, or treat cardiac failure, and 36 provide long-term management of this condition during diabetes.